Clinical trial NCT02952508: Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
Official title: An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Waldenstrom Macroglobulinemia
Multiple Myeloma
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Lymphoplasmacytic Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Diffuse Large B Cell Lymphoma
Central Nervous System Lymphoma
Keywords: Waldenstrom Macroglobulinemia
Non-Hodgkin Lymphoma
NHL
Relapsed
Refractory
Novel class
Pivotal
Phase 3
Hematologic disease
Neoplasm
Plasma cell neoplasms
Paraproteinemias
Lymphoma
Immunoproliferative disorder
Blood protein disorders
Lymphoproliferative disorders
Antineoplastic agents
Lead sponsor: Cellectar Biosciences, Inc.
Sponsor class: INDUSTRY
First posted: 2016-11-02
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of iopofosine I 131 in patients with WM that have received at least two prior lines of therapy.

Detailed description: B-cell malignancies represent a diverse collection of diseases and, taken together, make up the majority of hematologic malignancies. B-cell lymphomas represent the largest percentage of these neoplasms, and the relapsed and/or refractory B-cell lymphomas have proven very difficult to treat. Patients that have failed prior therapy, including WM patients, represent a very challenging patient population with significantly reduced life-expectancy.

Iopofosine I 131 is a targeted radiotherapeutic that exploits the selective uptake and retention of Cellectar's proprietary phospholipid ethers (PLEs) by malignant cells. Cellectar Biosciences' novel cancer-targeted small-molecule compound is radiolabeled with the radioisotope iodine-131 (I-131) which has previously been used approved for use in select tumors. Iopofosine I 131 has been evaluated in over 80 xenograft and spontaneous (transgenic) tumor models where it was demonstrated to be effective in eliminating tumors.

Based on the critical unmet medical need for effective agents with novel mechanisms of action in B-cell malignancies, Cellectar Biosciences has chosen to expand this ongoing study to assess iopofosine I 131 in a pivotal expansion cohort in Waldenstrom's Macroglobulinemia patients that have received at least two prior lines of therapy.

Eligibility criteria: \[CLOVER-1\] Inclusion Criteria: All Patients

* Histologically or cytologically confirmed MM; Patients with primary or secondary CNSL may be enrolled.
* ECOG performance status of 0 to 2
* 18 years of age or older
* Life expectancy of at least 6 months
* Platelets ≥ 75,000/µL (if full-dose anticoagulation therapy is used, platelets ≥ 100,000/µL are required)
* WBC count ≥ 3000/µL
* Absolute neutrophil count ≥ 1500/µL
* Hemoglobin ≥ 9 g/dL (last transfusion, if any, must be at least 1 week prior to study registration, and no transfusions are allowed between registration and dosing)
* Estimated glomerular filtration rate ≥ 30 mL/min/1.73 m2
* Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN)
* Bilirubin \< 1.5 × ULN
* International normalized ratio (INR) \< 2.5
* If patient is on full-dose anticoagulation therapy, the anticoagulation therapy must be reversible and reversal of the anticoagulation therapy must not be life-threatening, as judged by the Investigator
* Patients who have undergone stem cell transplant must be at least 100 days from transplant

Patients with Multiple Myeloma

* At least 5 prior regimens, which must include at least 1 approved proteasome inhibitor (bortezomib, carfilzomib, or ixazomib), at least 1 approved immunomodulatory agent (thalidomide, lenalidomide, or pomalidomide), and at least 1 approved monoclonal antibody (e.g., daratumumab or elotuzumab) with or without maintenance therapy, unless patients are intolerable to such agents or ineligible to receive such agents.
* At least triple-class refractory (refractory to a proteasome inhibitor, immunomodulatory agent, and a monoclonal antibody)
* Progressive disease defined by any of the following:

  * 25% increase in serum M-protein from the lowest response value during (or after) last therapy and/or absolute increase in serum M-protein of ≥ 0.5 g/dL
  * 25% increase in urine M-protein from the lowest response value during (or after) last therapy and/or absolute increase in urine M-protein of ≥ 200 mg/24 h
  * 25% increase in bone marrow plasma cell percentage from the lowest response value during (or after) last therapy. Absolute bone marrow plasma cell percentage must be ≥ 10% unless prior CR when absolute bone marrow plasma cell percentage must be ≥ 5%.
  * 25% increase in serum FLC level from the lowest response value during (or after) last therapy; the absolute increase must be \> 10 mg/dL
  * New onset hypercalcemia \> 11.5 mg/dL
  * Failure to obtain a partial response or better to current treatment, or cannot further improve their response to current treatment
  * Appearance of new extramedullary disease
* Measurable disease defined by any of the following:

  * Serum M-protein \> 0.5 g/dL
  * Urine M-protein \> 200 mg/24 h
  * Serum FLC assay: Involved FLC level ≥ 10 mg/dL provided serum FLC ratio is abnormal.

\[CLOSED\] Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma/Waldenstom Macroglobulinemia, or Marginal Zone Lymphoma

* Prior treatment with at least 2 prior regimens, which may include chemotherapy, an approved anti-CD20 antibody with or without maintenance therapy, and an approved targeted agent, unless patients are ineligible to receive such agents
* Patients with Helicobacter pylori+ mucosa-associated lymphoid tissue lymphoma must have received 1 prior antibiotic regimen for H pylori
* At least 1 measurable nodal lesion with longest diameter \> 15 mm or 1 measurable extranodal lesion (eg, hepatic nodule) with longest diameter \> 10 mm. Additional parameters (e.g., measurable IgM for patients with Lymphoplasmacytic Lymphoma) may be allowed if they meet current NCCN guidelines for symptomatic disease. Patients with uptake by FDG-PET scan may be allowed with prior approval of Sponsor.

\[CLOSED\] Patients with Mantle Cell Lymphoma

* Prior treatment with at least 1 prior regimen
* At least 1 measurable nodal lesion with longest diameter \> 15 mm or 1 measurable extranodal lesion (eg, hepatic nodule) with longest diameter \> 10 mm. Patients with uptake by FDG-PET scan may be allowed with prior approval of Sponsor.

\[CLOSED\] Patients with Diffuse Large B-Cell Lymphoma

* Relapsed or refractory to combination chemotherapy for DLBCL that contains rituximab and an anthracycline; or is intolerable to such agents. Relapsed disease is defined as either recurrence of disease after a CR or PD after achieving a partial response (PR) or SD. Refractory disease is defined as failure to achieve at least SD with any 1 line of therapy or with PD ≤ 3 months of the most recent chemotherapy regimen.
* At least 1 measurable nodal lesion with longest diameter \> 15 mm or 1 measurable extranodal lesion (eg, hepatic nodule) with longest diameter \> 10 mm. Patients with uptake by FDG-PET scan may be allowed with prior approval of Sponsor.

Patients with CNS Lymphoma

* Must have biopsy-proven disease and must have received at least one prior intervention for their disease.
* Must be at least two weeks from CNS biopsy before administration of iopofosine I 131.
* Must have at least one lesion with enhancement on brain imaging.
* Stable (or decreasing) dose of corticosteroids or anti-convulsant medication for at least 7 days prior to dosing

\[CLOVER-1\] Exclusion Criteria:

* Ongoing Grade 2 or greater toxicities due to previous therapies. Stable, tolerable Grade 2 AEs (eg, neuropathy) may be allowed.
* Prior external-beam RT resulting in greater than 20% of total bone marrow receiving greater than 20 Gy.
* Prior total body or hemi-body irradiation. Patients who have received prior low-dose total body or hemi-body irradiation may be allowed on a case-by-case basis after discussion with Sponsor (considerations may include factors such as time since irradiation, total lifetime accumulated dose, etc.)
* Extradural tumor in contact with the spinal cord or tumor located where swelling in response to therapy may impinge upon the spinal cord
* For patients with CLL/SLL, LPL, or MZL, transformation to a more aggressive form of NHL
* Ongoing chronic immunosuppressive therapy
* Clinically significant bleeding event within prior 6 months
* Ongoing anti-platelet therapy (except low-dose aspirin \[eg, 81 mg daily\] for cardioprotection)
* Anti-cancer therapy within two weeks of initial iopofosine I 131 infusion. Low dose dexamethasone for symptom management is allowed
* Radiation therapy, chemotherapy, immunotherapy, or investigational therapy within 2 weeks of eligibility-defining bone marrow biopsy.
* For patients with primary or secondary CNSL, active bleeding in the tumor bed and/or uncontrolled seizure activity

\[CLOVER-WaM\] Inclusion Criteria

* Histologically or cytologically confirmed WM. Patients with a diagnosis of LPL may be enrolled with prior Sponsor approval.
* Patient has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2 (Appendix C)
* Patient is 18 years of age or older
* Life expectancy of at least 6 months
* Received at least two prior lines of therapy for WM
* Measurable IgM (above upper limit of normal) OR at least one measurable nodal lesion with longest diameter \> 15 mm or one measurable extranodal lesion (e.g., hepatic nodule) with longest diameter \> 10 mm

\[CLOVER-WaM\] Exclusion Criteria

* Ongoing Grade 2 or greater toxicities due to previous therapies, excluding alopecia.
* Prior external-beam RT resulting in greater than 20% of total bone marrow receiving greater than 20 Gy.
* Prior total body or hemi-body irradiation. Patients who have received prior low-dose total body or hemi-body irradiation may be allowed on a case-by-case basis after discussion with Sponsor (considerations may include factors such as time since irradiation, total lifetime accumulated dose, etc.)
* Patients with second malignancies in addition to WM, if the second malignancy has required therapy in the last 2 years or is not in remission; exceptions to this criterion include successfully treated non-metastatic basal cell or squamous cell skin carcinoma, or prostate cancer that does not require therapy
* Anti-cancer therapy within two weeks of initial iopofosine I 131 infusion.
* Need for acute treatment of WM (e.g., those with hyperviscosity)

Primary outcomes:
measure: Part A [CLOVER-1] Clinical benefit rate
timeFrame: 84 days
measure: Part B [CLOVER-WaM] Major Response Rate
timeFrame: 12 months
Secondary outcomes:
measure: Part A [CLOVER-1] Overall Response Rate
timeFrame: 135 days
measure: Part A [CLOVER-1] Progression Free Survival
timeFrame: 135 days
measure: Part A [CLOVER-1] Time to Next Treatment
timeFrame: 3 years
measure: Part A [CLOVER-1] Overall Survival
timeFrame: 135 days
measure: Part A [CLOVER-1] Duration of Response
timeFrame: 135 days
measure: Part B [CLOVER-WaM] Overall Response Rate
timeFrame: 135 days
measure: Part B [CLOVER-WaM] Treatment Free Survival
timeFrame: 135 days
measure: Part B [CLOVER-WaM] Duration of Response
timeFrame: 135 days
measure: Part B [CLOVER-WaM] Clinical Benefit Rate
timeFrame: 135 days
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Cellectar Biosciences site
state: California
city: Redlands
country: United States
facility: Cellectar Biosciences site
state: California
city: Washington
country: United States
facility: Cellectar Biosciences site
state: District of Columbia
city: Jacksonville
country: United States
facility: Cellectar Biosciences site
state: Florida
city: Miami
country: United States
facility: Cellectar Biosciences site
state: Florida
city: Tampa
country: United States
facility: Cellectar Biosciences site
state: Florida
city: Atlanta
country: United States
facility: Cellectar Biosciences
state: Georgia
city: Maywood
country: United States
facility: Cellectar Biosciences site
state: Illinois
city: Warrenville
country: United States
facility: Cellectar Biosciences site
state: Illinois
city: Westwood
country: United States
facility: Cellectar Biosciences site
state: Kansas
city: New Orleans
country: United States
facility: Cellectar Biosciences site
state: Louisiana
city: Baltimore
country: United States
facility: Cellectar Biosciences site
state: Maryland
city: Bethesda
country: United States
facility: Cellectar Biosciences
state: Maryland
city: Boston
country: United States
facility: Cellectar Biosciences site
state: Massachusetts
city: North Bergen
country: United States
facility: Cellectar Biosciences
state: New Jersey
city: Buffalo
country: United States
facility: Cellectar Biosciences site
state: New York
city: New York
country: United States
facility: Cellectar Biosciences site
state: New York
city: Rochester
country: United States
facility: Cellectar Biosciences site
state: New York
city: Durham
country: United States
facility: Cellectar Biosciences site
state: North Carolina
city: Canton
country: United States
facility: Cellectar Biosciences
state: Ohio
city: Cincinnati
country: United States
facility: Cellectar Biosciences site
state: Ohio
city: Charleston
country: United States
facility: Cellectar Biosciences Site
state: South Carolina
city: Greenville
country: United States
facility: Cellectar Biosciences
state: South Carolina
city: Knoxville
country: United States
facility: Cellectar Biosciences site
state: Tennessee
city: Dallas
country: United States
facility: Cellectar Biosciences site
state: Texas
city: Dallas
country: United States
facility: Cellectar Biosciences site
state: Texas
city: Houston
country: United States
facility: Cellectar Biosciences site
state: Texas
city: Seattle
country: United States
facility: Cellectar Biosciences site
state: Washington
city: Madison
country: United States
facility: Cellectar Biosciences site
state: Wisconsin
city: Concord
country: Australia
facility: Cellectar Biosciences site
state: New South Wales
city: Adelaide
country: Australia
facility: Cellectar Biosciences
state: South Australia
city: Salvador
country: Brazil
facility: Cellectar Biosciences
state: Bahia
city: Curitiba
country: Brazil
facility: Cellectar Biosciences
state: Parana
city: Porto Alegre
country: Brazil
facility: Cellectar Biosciences
state: RioGrande Do Sul
city: Blumenau
country: Brazil
facility: Cellectar Biosciences
state: Santa Catarina
city: Hradec Králové
country: Czechia
facility: Cellectar Biosciences Site
city: Helsinki
country: Finland
facility: Cellectar Biosciences
city: Pessac
country: France
facility: Cellectar Biosciences
city: Poitiers
country: France
facility: Cellectar Biosciences
city: Athens
country: Greece
facility: Cellectar Biosciences site
city: Rio
country: Greece
facility: Cellectar Biosciences Site
city: Jerusalem
country: Israel
facility: Cellectar Biosciences Site
city: Barcelona
country: Spain
facility: Cellectar Biosciences
city: Barcelona
country: Spain
facility: Cellectar Biosciences site
city: Madrid
country: Spain
facility: Cellectar Biosciences
city: Madrid
country: Spain
facility: Cellectar Biosciences
city: Salamanca
country: Spain
facility: Cellectar Biosciences
city: Zaragoza
country: Spain
facility: Cellectar Biosciences site
city: Ankara
country: Turkey
facility: Cellectar Biosciences
city: Bornova
country: Turkey
facility: Cellectar Biosciences
city: Istanbul
country: Turkey
facility: Cellectar Biosciences
city: London
country: United Kingdom
facility: Cellectar Biosciences site
Study officials:
affiliation: Cellectar Biosciences
name: Jarrod Longcor
role: STUDY_DIRECTOR
References: